Imatinib Teva (Imatinib)

Imatinib acts on malignant cells driven by abnormal tyrosine‑kinase signaling, making it a cornerstone therapy for several hematologic and solid tumours.

• Chronic myeloid leukemia: suppresses BCR‑ABL activity to achieve hematologic and cytogenetic remission.
• Gastrointestinal stromal tumor: inhibits KIT and PDGFRA mutations to control tumor growth.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks BCR‑ABL driven proliferation to improve remission rates.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, KIT, and PDGFRA tyrosine kinases, stabilising them in an inactive conformation. This prevents phosphorylation of downstream substrates, halting proliferative signaling pathways and inducing apoptosis in cells dependent on these kinases for survival.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Fatigue: generalized tiredness.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Diarrhea: loose stools.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiotoxicity: congestive heart failure or reduced ejection fraction.
• Severe neutropenia: marked decrease in white blood cells.
• Hemorrhagic events: bleeding tendencies.
• Pulmonary hypertension: increased pressure in lung arteries.
• Anaphylaxis: rare severe allergic reaction.

Patients receiving Imatinib should be monitored for specific safety considerations.

• Baseline liver function: assess hepatic enzymes before initiation.
• Cardiac assessment: evaluate heart function in patients with pre‑existing cardiac disease.
• Hematologic monitoring: regular blood counts to detect neutropenia or anemia.
• Drug interactions: review concomitant medications for CYP3A4 modulators.
• Pregnancy and lactation: discuss risks with a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Imatinib may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may modestly affect bioavailability.
• Warfarin: monitor INR as Imatinib can enhance anticoagulant effect.
• Vaccines: live attenuated vaccines should be avoided during treatment.